entertainment -WSS

entertainment

author：explore 2025-09-29 01:38:00 - browse：94727

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Wellcome Trust names Røttingen as its new CEO

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

The Readout: Gilead, Bernie Sanders, and other pharma news

Why did Pfizer dish out millions for a Super Bowl ad?

Akero's treatment for NASH falls short in cirrhosis study

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Better Therapeutics data on benefit with GLP

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

KalVista pill reduced swelling 'attacks' caused by genetic disease

Sports medicine is finally prioritizing gender equality

Cancer cells are shown to suck energy source from immune cells

Medical records are filled with copy

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Novavax promises a turnaround & Lilly roils the obesity market

There’s no way to know how good AI health technologies are

In Memoriam: Notable people who died in 2023

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

entertainment

European regulators consider appeal over Amylyx ALS drug

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Biogen Alzheimer’s drug launch off to slow start

What should King Charles tell the public about his cancer?

Wellcome Trust names Røttingen as its new CEO

A disappointing year of Humira biosimilars

Wikipedia

knowledge

knowledge

leisure time